We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Alnylam Presents New Pre-clinical Data on ALN-AT3

News   Dec 10, 2013

 
Alnylam Presents New Pre-clinical Data on ALN-AT3
 
 
Advertisement
 

RELATED ARTICLES

FDA Grants Fast Track Designation to Onvansertib for Second-line Treatment of KRAS-mutated Colorectal Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

READ MORE

New Insights Into RNA Movements Could Be Used To Treat Cancer

News

New research suggests that an RNA molecule involved in preventing tumor formation can change its structure and thereby control protein production in the cell, which could have implications for cancer treatment.

READ MORE

Trial Investigates Remdesivir–Baricitinib Combo as COVID-19 Treatment

News

Following on from remdesivir’s promising results from previous studies, a new trial is now investigating remdesivir in combination with baricitinib or placebo as a treatment for COVID-19, in a double-blind, randomized trial.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE